Lerapolturev
- Generic Name
- Lerapolturev
- Drug Type
- Biotech
- CAS Number
- 2430048-02-3
- Unique Ingredient Identifier
- MQ5GV2WUK4
Lerapolturev (PVSRIPO) in GBM
- Conditions
- Recurrent Supratentorial Glioblastoma
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 92
- Registration Number
- NCT06177964
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
- Conditions
- Solid TumorNon-muscle-invasive Bladder CancerBladder Cancer
- Interventions
- Other: 5% DDM
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04690699
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
- Conditions
- Melanoma
- Interventions
- Biological: Anti-PD-1 Checkpoint Inhibitor
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04577807
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
- Conditions
- Supratentorial GlioblastomaBrain TumorGlioblastomaRecurrent Glioblastoma
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04479241
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
PVSRIPO for Patients With Unresectable Melanoma
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Istari Oncology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03712358
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.